Quintrio
Home

MEDICINAL CHEMICALS & BOTANICAL PRODUCTS

Niagen Bioscience, Inc. Common Stock

NAGE

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

Last trade $2.01
Day change $0.00 (0.00%)
Day range $1.96 – $2.09
Volume 721,254
Market cap $159M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$159.19M
Price / earnings
15.55×
Price / book
1.92×
Price / sales
1.3×
EV / sales
0.73×
EV / EBITDA
15.05×

Profitability

Earnings per share
$0.13
Return on assets
9.42%
Return on equity
12.33%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
5.93×
Quick ratio
4.71×
Cash ratio
4.11×

Cash flow

Price / cash flow
32.61×
Price / free cash flow
34.76×
Free cash flow
$4.58M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NAGE, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025
Revenue$27.19M$29.79M$31.47M$33.84M$33.99M$31.12M$30.48M
Cost of revenue$10.09M$10.47M$11.5M$12.14M$12.06M$10.89M$11.15M
Gross profit$17.11M$19.31M$19.98M$21.7M$21.93M$20.23M$19.33M
Selling, general and administrative$16.9M$17.1M$16.92M$17.89M$15.9M$15.47M$13.3M
Research and development$1.8M$1.51M$1.48M$1.71M$1.8M$1.57M$1.26M
Total operating expenses$18.69M$18.61M$18.4M$17.62M$17.69M$17.04M$14.56M
Operating income-$1.59M$700K$1.58M$4.09M$4.24M$3.19M$4.77M
Interest expense$414K$372K$375K$0$564K$552K$459K
Income before taxes-$1.17M$1.07M$6.74M$4.42M$4.8M$3.74M$5.23M
Income taxes$0$106K$417K$292K$222K$128K$168K
Net income-$1.17M$963K$6.32M$4.13M$4.58M$3.61M$5.06M
Net income attributable to common shareholders-$1.17M$963K$6.32M$4.13M$4.58M$3.61M$5.06M
EBITDA-$1.3M$991K$1.87M$4.4M$4.43M$3.38M$4.97M
Basic earnings per share-$0.01$0.01$0.08$0.05$0.06$0.05$0.07
Diluted earnings per share-$0.01$0.01$0.07$0.05$0.05$0.04$0.06

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Niagen Bioscience (NAGE) Reports Q3 Loss, Lags Revenue Estimates

Niagen Bioscience reported a quarterly loss of $0.01 per share, meeting consensus estimates but missing revenue expectations by 9.81% with $27.19 million in quarterly revenues, down from $33.99 million year-over-year. The stock has declined 62.9% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions.

Zacks Investment Research

Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know

Coherus Oncology is expected to report a quarterly loss of $0.22 per share with revenues of $15.9 million when it releases Q3 2026 results on November 9. While revenues are expected to grow 37.4% year-over-year, the company has a negative Earnings ESP of -1.54% and has failed to beat consensus estimates in the last four quarters, making it an unlikely candidate for an earnings beat.

Zacks Investment Research

Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline

Niagen Bioscience is expected to report Q3 2026 earnings on November 4 with a projected loss of $0.01 per share and revenues declining 11.3% year-over-year to $30.15 million. The company has a negative Earnings ESP of -500% and Zacks Rank #4, making it unlikely to beat consensus estimates. The stock does not appear to be a compelling earnings-beat candidate.

Benzinga

Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion— Stock Jumps After-Hours (UPDATED)

Niagen Bioscience (NASDAQ: NAGE) reported doubled annual profits and 30% revenue growth for 2025, reaching $129.4 million in net sales. CEO Rob Fried announced the company is actively pursuing acquisitions and expanding into new markets including at-home injection kits and cosmetics partnerships. However, 2026 guidance of $145 million (15% growth) appears more modest, and the stock trades 60% below its 52-week high despite strong fundamentals.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Dec 7, 20063.189-for-1forward split